
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2016

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation

I.R.S. Employer Identification No.
36-0698440

100 Abbott Park Road
Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ☒

Accelerated Filer ☐

Non-Accelerated Filer ☐

Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, 2016, Abbott Laboratories had 1,469,995,415 common shares without par value outstanding.

[Table of Contents](#)

Abbott Laboratories

Table of Contents

[Part I - Financial Information](#)

Page

Item 1. Financial Statements and Supplementary Data

[Condensed Consolidated Statement of Earnings](#)

3

[Condensed Consolidated Statement of Comprehensive Income](#)

4

[Condensed Consolidated Balance Sheet](#)

5

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3. Quantitative and Qualitative Disclosures about Market Risk

26

Item 4. Controls and Procedures

26

Part II - Other Information

Item 1. Legal Proceedings

26

Item 1A. Risk Factors

26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 6. Exhibits

27

Signature

28

Table of Contents

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|--|-------------------------------|-----------|-----------------------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Net sales | \$ 5,333 | \$ 5,170 | \$ 10,218 | \$ 10,067 |
| Cost of products sold, excluding amortization of intangible assets | 2,287 | 2,218 | 4,427 | 4,299 |
| Amortization of intangible assets | 145 | 151 | 289 | 307 |
| Research and development | 348 | 345 | 727 | 658 |
| Selling, general and administrative | 1,737 | 1,727 | 3,435 | 3,464 |
| Total operating cost and expenses | 4,517 | 4,441 | 8,878 | 8,728 |
| Operating earnings | 816 | 729 | 1,340 | 1,339 |
| Interest expense | 103 | 44 | 161 | 81 |
| Interest (income) | (20) | (27) | (53) | (48) |
| Net foreign exchange loss (gain) | 10 | 5 | 488 | (49) |
| Other expense (income), net | 8 | (279) | 27 | (284) |
| Earnings from continuing operations before taxes | 715 | 986 | 717 | 1,639 |
| Taxes on earnings from continuing operations | 116 | 200 | 62 | 324 |
| Earnings from continuing operations | 599 | 786 | 655 | 1,315 |
| Earnings (loss) from discontinued operations, net of tax | 16 | (1) | 260 | 25 |
| Gain (loss) on sale of discontinued operations, net of tax | — | (1) | 16 | 1,736 |
| Net earnings (loss) from discontinued operations, net of tax | 16 | (2) | 276 | 1,761 |
| Net Earnings | \$ 615 | \$ 784 | \$ 931 | \$ 3,076 |
| Basic Earnings Per Common Share — | | | | |
| Continuing operations | \$ 0.40 | \$ 0.52 | \$ 0.44 | \$ 0.87 |
| Discontinued operations | 0.01 | — | 0.19 | 1.17 |
| Net earnings | \$ 0.41 | \$ 0.52 | \$ 0.63 | \$ 2.04 |
| Diluted Earnings Per Common Share — | | | | |
| Continuing operations | \$ 0.40 | \$ 0.52 | \$ 0.44 | \$ 0.87 |
| Discontinued operations | 0.01 | — | 0.19 | 1.16 |
| Net earnings | \$ 0.41 | \$ 0.52 | \$ 0.63 | \$ 2.03 |
| Cash Dividends Declared Per Common Share | \$ 0.26 | \$ 0.24 | \$ 0.52 | \$ 0.48 |
| Average Number of Common Shares Outstanding Used for Basic | | | | |
| Earnings Per Common Share | 1,474,504 | 1,493,771 | 1,476,161 | 1,500,285 |
| Dilutive Common Stock Options | 5,988 | 10,444 | 6,165 | 10,676 |

| | | | | |
|--|-----------|-----------|-----------|-----------|
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,480,492 | 1,504,215 | 1,482,326 | 1,510,961 |
| Outstanding Common Stock Options Having No Dilutive Effect | 5,673 | 658 | 5,673 | 658 |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

[Table of Contents](#)

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|--|-------------------------------|----------|-----------------------------|----------|
| | 2016 | 2015 | 2016 | 2015 |
| Net Earnings | \$ 615 | \$ 784 | \$ 931 | \$ 3,076 |
| Foreign currency translation (loss) gain adjustments | (104) | 84 | 317 | (827) |
| Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of \$(12) and \$(3) in 2016 and \$10 and \$25 in 2015 | (47) | 22 | (29) | 53 |
| Unrealized gains (losses) on marketable equity securities, net of taxes of nil in 2016 and \$256 and \$344 in 2015 | (213) | 522 | (756) | 695 |
| Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of \$(2) and \$(24) in 2016 and \$(6) and nil in 2015 | (8) | (25) | (97) | 1 |
| Other comprehensive income (loss) | (372) | 603 | (565) | (78) |
| Comprehensive Income | \$ 243 | \$ 1,387 | \$ 366 | \$ 2,998 |

| | June 30, 2016 | December 31, 2015 |
|--|------------------|----------------------|
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: | | |
| Cumulative foreign currency translation (loss) adjustments | \$ (4,512) | \$ (4,829) |
| Net actuarial (losses) and prior service cost and credits | (1,987) | (1,958) |
| Cumulative unrealized (losses) gains on marketable equity securities | (691) | 65 |
| Cumulative (losses) gains on derivative instruments designated as cash flow hedges and other | (33) | 64 |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

[Table of Contents](#)

Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)

| | June 30, 2016 | December 31, 2015 |
|---|------------------|----------------------|
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 2,578 | \$ 5,001 |
| Short-term investments | 1,860 | 1,124 |
| Trade receivables, less allowances of \$347 in 2016 and \$337 in 2015 | 3,567 | 3,418 |
| Inventories: | | |
| Finished products | 1,865 | 1,744 |
| Work in process | 340 | 316 |
| Materials | 608 | 539 |
| Total inventories | 2,813 | 2,599 |
| Prepaid expenses and other receivables | 2,104 | 1,908 |
| Current assets held for disposition | 66 | 105 |
| Total Current Assets | 12,988 | 14,155 |
| Investments | 3,339 | 4,041 |
| Property and equipment, at cost | 12,712 | 12,383 |
| Less: accumulated depreciation and amortization | 6,886 | 6,653 |
| Net property and equipment | 5,826 | 5,730 |
| Intangible assets, net of amortization | 5,311 | 5,562 |

| | | |
|---|------------------|------------------|
| Goodwill | 9,752 | 9,638 |
| Deferred income taxes and other assets | 2,613 | 2,119 |
| Non-current assets held for disposition | 2 | 2 |
| | <u>\$ 39,831</u> | <u>\$ 41,247</u> |
| Liabilities and Shareholders' Investment | | |
| Current Liabilities: | | |
| Short-term borrowings | \$ 2,892 | \$ 3,127 |
| Trade accounts payable | 1,153 | 1,081 |
| Salaries, wages and commissions | 717 | 746 |
| Other accrued liabilities | 2,931 | 3,043 |
| Dividends payable | 383 | 383 |
| Income taxes payable | 232 | 430 |
| Current portion of long-term debt | 4 | 3 |
| Current liabilities held for disposition | 361 | 373 |
| Total Current Liabilities | <u>8,673</u> | <u>9,186</u> |
| Long-term debt | 6,016 | 5,871 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 4,347 | 4,864 |
| Commitments and Contingencies | | |
| Shareholders' Investment: | | |
| Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | — | — |
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,705,266,590; 2015: 1,702,017,390 | 12,835 | 12,734 |
| Common shares held in treasury, at cost — Shares: 2016: 235,271,175; 2015: 229,352,338 | (10,821) | (10,622) |
| Earnings employed in the business | 25,884 | 25,757 |
| Accumulated other comprehensive income (loss) | (7,223) | (6,658) |
| Total Abbott Shareholders' Investment | <u>20,675</u> | <u>21,211</u> |
| Noncontrolling Interests in Subsidiaries | 120 | 115 |
| Total Shareholders' Investment | <u>20,795</u> | <u>21,326</u> |
| | <u>\$ 39,831</u> | <u>\$ 41,247</u> |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

[Table of Contents](#)

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)

| | Six Months Ended June 30 | |
|---|--------------------------|------------|
| | 2016 | 2015 |
| Cash Flow From (Used in) Operating Activities: | | |
| Net earnings | \$ 931 | \$ 3,076 |
| Adjustments to reconcile net earnings to net cash from operating activities - | | |
| Depreciation | 405 | 416 |
| Amortization of intangible assets | 289 | 307 |
| Share-based compensation | 214 | 205 |
| Impact of currency devaluation | 477 | — |
| Gain on sale of discontinued operations | (25) | (2,820) |
| Gain on sale of Mylan shares | — | (207) |
| Trade receivables | (150) | (125) |
| Inventories | (149) | (210) |
| Other, net | (1,176) | 301 |
| Net Cash From Operating Activities | <u>816</u> | <u>943</u> |
| Cash Flow From (Used in) Investing Activities: | | |
| Acquisitions of property and equipment | (490) | (451) |
| Proceeds from business disposition | 25 | 230 |
| Acquisitions of businesses and technologies, net of cash acquired | (7) | (4) |
| Proceeds from the sale of Mylan shares | — | 2,290 |
| Sales (Purchases) of other investment securities, net | (800) | (2,056) |
| Other | 28 | 28 |
| Net Cash (Used in) From Investing Activities | <u>(1,244)</u> | <u>37</u> |
| Cash Flow From (Used in) Financing Activities: | | |
| Net (repayments of) proceeds from issuance of short-term debt and other | (285) | (1,518) |
| Proceeds from the issuance of long-term debt | — | 2,485 |
| Repayments of long-term debt | (10) | (33) |
| Payment of debt issuance costs | (132) | — |
| Payment of contingent consideration | (25) | — |
| Purchases of common shares | (520) | (1,347) |

| | | |
|---|----------|----------|
| Proceeds from stock options exercised, including income tax benefit | 130 | 213 |
| Dividends paid | (769) | (724) |
| Net Cash (Used in) Financing Activities | (1,611) | (924) |
| Effect of exchange rate changes on cash and cash equivalents | (384) | (71) |
| Net Decrease in Cash and Cash Equivalents | (2,423) | (15) |
| Cash and Cash Equivalents, Beginning of Year | 5,001 | 4,063 |
| Cash and Cash Equivalents, End of Period | \$ 2,578 | \$ 4,048 |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

[Table of Contents](#)

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

June 30, 2016

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott's Annual Report on Form 10-K for the year ended December 31, 2015. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — Discontinued Operations

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for 110 million shares (or approximately 22%) of a newly formed entity (Mylan N.V.) that combined Mylan's existing business and Abbott's developed markets branded generics pharmaceuticals business. Mylan N.V. is publicly traded. Historically, this business was included in Abbott's Established Pharmaceutical Products segment. Abbott retained its branded generics pharmaceuticals business in emerging markets. At the date of closing, the 110 million Mylan N.V. shares that Abbott received were valued at \$5.77 billion and Abbott recorded an after-tax gain on the sale of the business of approximately \$1.6 billion. The shareholder agreement with Mylan N.V. includes voting and other restrictions that prevent Abbott from exercising significant influence over the operating and financial policies of Mylan N.V.

At the close of this transaction, Abbott and Mylan entered into a transition services agreement pursuant to which Abbott and Mylan are providing various back office support services to each other on an interim transitional basis. Transition services may be provided for up to 2 years. Charges by Abbott under this transition services agreement are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transition support does not constitute significant continuing involvement in Mylan's operations. Abbott also entered into manufacturing supply agreements with Mylan related to certain products, with the supply term ranging from 3 to 10 years and requiring a 2 year notice prior to termination. The cash flows associated with these transition services and manufacturing supply agreements are not expected to be significant, and therefore, these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205.

In April 2015, Abbott sold 40.25 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. In the second quarter of 2015, Abbott recorded a pretax gain of \$207 million on \$2.29 billion in net proceeds from the sale of these shares. The gain was recognized in the Other (income) expense line of the Condensed Consolidated Statement of Earnings. As a result of this sale, Abbott's ownership interest in Mylan N.V. decreased to approximately 14%.

On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. Abbott received cash proceeds of \$230 million and reported an after-tax gain on the sale of approximately \$130 million in the first quarter of 2015. In the first quarter of 2016, Abbott received an additional \$25 million of proceeds related to the expiration of a holdback agreement associated with the sale of this business and reported an after-tax gain on the sale of discontinued operations of \$16 million.

As a result of the disposition of the above businesses, the operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from Discontinued Operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses up to the date of disposition are included in Abbott's Condensed Consolidated Statement of Cash Flows.

On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott's research-based proprietary pharmaceuticals business. For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 and 2014. These assets and liabilities have been presented as held for disposition in the

[Table of Contents](#)

Condensed Consolidated Balance Sheet. Abbott has recorded a prepaid asset of \$293 million for its obligation to transfer these net liabilities held for disposition to

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income related taxes attributable to AbbVie's business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Net earnings from discontinued operations in the first six months of 2016 and 2015 reflect the recognition of \$263 million and \$17 million, respectively, of net tax benefits as a result of the resolution of various tax positions related to AbbVie's operations for years prior to the separation.

The following table summarizes the components of discontinued operations:

| (in millions) | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|-------------------------------|---------------|-----------------------------|---------------|
| | 2016 | 2015 | 2016 | 2015 |
| Net Sales | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ — | \$ — | \$ — | \$ 256 |
| AbbVie | — | — | — | — |
| Total | <u>\$ —</u> | <u>\$ —</u> | <u>\$ —</u> | <u>\$ 256</u> |
| Earnings (Loss) Before Tax | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ (3) | \$ (5) | \$ (6) | \$ 20 |
| AbbVie | — | — | — | — |
| Total | <u>\$ (3)</u> | <u>\$ (5)</u> | <u>\$ (6)</u> | <u>\$ 20</u> |
| Income Tax Expense (Benefit) | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ — | \$ — | \$ (3) | \$ 12 |
| AbbVie | (19) | (4) | (263) | (17) |
| Total | <u>\$ (19)</u> | <u>\$ (4)</u> | <u>\$ (266)</u> | <u>\$ (5)</u> |
| Net Earnings (Loss) | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ (3) | \$ (5) | \$ (3) | \$ 8 |
| AbbVie | 19 | 4 | 263 | 17 |
| Total | <u>\$ 16</u> | <u>\$ (1)</u> | <u>\$ 260</u> | <u>\$ 25</u> |

The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first six months of 2015 resulted in the recognition of a pretax gain of \$2.820 billion, tax expense of \$1.084 billion and an after-tax gain of \$1.736 billion.

The assets and liabilities held for disposition as of June 30, 2016 and December 31, 2015, relate to the AbbVie businesses. The following is a summary of the assets and liabilities held for disposition:

| (in millions) | June 30, 2016 | December 31, 2015 |
|--|------------------|----------------------|
| Cash and Trade receivables, net | \$ 41 | \$ 54 |
| Total inventories | 20 | 43 |
| Prepaid expenses and other receivables | 5 | 8 |
| Current assets held for disposition | 66 | 105 |
| Net property and equipment | 1 | 1 |
| Deferred income taxes and other assets | 1 | 1 |
| Non-current assets held for disposition | 2 | 2 |
| Total assets held for disposition | <u>\$ 68</u> | <u>\$ 107</u> |
| Trade accounts payable | \$ 360 | \$ 359 |
| Salaries, wages, commissions and other accrued liabilities | 1 | 14 |
| Current liabilities held for disposition | 361 | 373 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | — | — |
| Total liabilities held for disposition | <u>\$ 361</u> | <u>\$ 373</u> |

[Table of Contents](#)

Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended June 30, 2016 and 2015 were \$597 million and \$783 million, respectively and for the six months ended June 30, 2016 and 2015 were \$652 million and \$1.3 billion, respectively. Net earnings allocated to common shares for the three months ended June 30, 2016 and 2015 were \$612 million and \$780 million, respectively, and for the six months ended June 30, 2016 and 2015 were \$927 million and \$3.1 billion, respectively.

Other (income) expense, net in the second quarter of 2015 primarily relates to a \$207 million gain on the sale of a portion of Abbott's position in Mylan stock and \$79 million of income resulting from a decrease in the fair value of contingent consideration related to a business acquisition. In the second quarter of 2015, Abbott sold 40.3 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. Abbott received \$2.29 billion in net proceeds from the sale of these shares. As a result of this sale, Abbott's ownership interest in Mylan N.V. decreased from approximately 22% to approximately 14%.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2016 and 2015 includes the effects of contributions to defined benefit plans of \$524 million and \$547 million, respectively, and to the post-employment medical and dental benefit plans of \$9 million and \$24 million, respectively. The first six months of 2016 also includes the non-cash impact of approximately \$410 million of net tax benefits primarily associated with the resolution of various tax positions from prior years, as well as cash taxes paid of approximately \$140 million related to the disposition of businesses. The first six months of 2015

includes the non-cash impact of approximately \$1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first six months of 2016 reduced Abbott's cash by approximately \$410 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows.

Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. GAAP. In 2014 and 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. These mechanisms included the CENCOEX, SICAD, and SIMADI rates, which stood at 6.3, 13.5, and approximately 200, respectively, at December 31, 2015. In 2015, Abbott continued to use the CENCOEX rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela.

On February 17, 2016, the Venezuelan government announced that the three-tier exchange rate system would be reduced to two rates renamed the DIPRO and DICOM rates. The DIPRO rate is the official rate for food and medicine imports and was adjusted from 6.3 to 10 bolivars per U.S. dollar. The DICOM rate is a floating market rate published daily by the Venezuelan central bank, which at the end of the first quarter of 2016 was approximately 263 bolivars per U.S. dollar. As a result of decreasing government approvals to convert bolivars to U.S. dollars to pay for intercompany accounts, as well as the accelerating deterioration of economic conditions in the country, Abbott concluded that it was appropriate to move to the DICOM rate at the end of the first quarter of 2016. As a result, Abbott recorded a foreign currency loss of \$477 million in the first quarter of 2016 to revalue its net monetary assets in Venezuela. Abbott is continuing to use the DICOM rate to report the results of operations and to remeasure net monetary assets for Venezuela at the end of each quarter. As of June 30, 2016, Abbott's Venezuelan operations represented approximately 0.1% of Abbott's consolidated assets and any additional foreign currency losses related to Venezuela are not expected to be material.

The components of long-term investments as of June 30, 2016 and December 31, 2015 are as follows:

| Long-term Investments (in millions) | June 30, 2016 | December 31, 2015 |
|--|------------------|----------------------|
| Equity securities | \$ 3,288 | \$ 4,014 |
| Other | 51 | 27 |
| Total | <u>\$ 3,339</u> | <u>\$ 4,041</u> |

9

[Table of Contents](#)

Note 4—Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

| (in millions) | Three Months Ended June 30 | | | | | | | |
|--|---|-------------------|---|-------------------|--|---------------|---|---------------|
| | Cumulative Foreign Currency Translation Adjustments | | Net Actuarial Losses and Prior Service Costs and Credits | | Cumulative Unrealized Gains (Losses) on Marketable Equity Securities | | Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges | |
| | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 |
| Balance at March 31 | \$ (4,408) | \$ (3,727) | \$ (1,940) | \$ (2,179) | \$ (478) | \$ 174 | \$ (25) | \$ 125 |
| Other comprehensive income (loss) before reclassifications | (104) | 84 | (62) | — | (213) | 660 | 11 | 5 |
| Amounts reclassified from accumulated other comprehensive income | — | — | 15 | 22 | — | (138) | (19) | (30) |
| Net current period comprehensive income (loss) | (104) | 84 | (47) | 22 | (213) | 522 | (8) | (25) |
| Balance at June 30 | <u>\$ (4,512)</u> | <u>\$ (3,643)</u> | <u>\$ (1,987)</u> | <u>\$ (2,157)</u> | <u>\$ (691)</u> | <u>\$ 696</u> | <u>\$ (33)</u> | <u>\$ 100</u> |

| (in millions) | Six Months Ended June 30 | | | | | | | |
|--|---|-------------------|---|-------------------|--|---------------|---|---------------|
| | Cumulative Foreign Currency Translation Adjustments | | Net Actuarial Losses and Prior Service Costs and Credits | | Cumulative Unrealized Gains (Losses) on Marketable Equity Securities | | Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges | |
| | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 |
| Balance at December 31, 2015 and 2014 | \$ (4,829) | \$ (2,924) | \$ (1,958) | \$ (2,229) | \$ 65 | \$ 1 | \$ 64 | \$ 99 |
| Impact of business dispositions | — | 108 | — | 19 | — | — | — | — |
| Other comprehensive income (loss) before reclassifications | 317 | (827) | (62) | — | (756) | 833 | (47) | 48 |
| Amounts reclassified from accumulated other comprehensive income | — | — | 33 | 53 | — | (138) | (50) | (47) |
| Net current period comprehensive income (loss) | 317 | (827) | (29) | 53 | (756) | 695 | (97) | 1 |
| Balance at June 30 | <u>\$ (4,512)</u> | <u>\$ (3,643)</u> | <u>\$ (1,987)</u> | <u>\$ (2,157)</u> | <u>\$ (691)</u> | <u>\$ 696</u> | <u>\$ (33)</u> | <u>\$ 100</u> |

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange loss (gain); gains (losses) on marketable equity securities as Other (income) expense, net and cash flow hedges as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit plan costs; see Note 11 for additional details.

Note 5 — Business Acquisitions

In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately \$225 million in cash plus additional payments up to \$150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The preliminary allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately \$220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately \$142 million, other assets of approximately \$13 million, net deferred tax liabilities of approximately \$80 million, and contingent consideration of approximately \$70 million. The preliminary allocations of the fair value of this acquisition will be finalized when the valuation is completed.

Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts.

On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately \$2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott's global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On March 15, 2016, Alere filed a Form 8-K stating that it will not be able to file its 2015 Form 10-K until it completes its analysis of the timing of revenue recognition in Africa and China. In its Form 8-K, Alere also stated that it does not expect to mail a definitive proxy statement related to obtaining the Alere shareholders' approval of the acquisition by Abbott until after Alere files its 2015 Form 10-K. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott's potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

On July 14, 2016, Alere filed a Form 8-K reporting that it had issued a press release announcing certain preliminary unaudited financial information for the fiscal year ended December 31, 2015 and the three months ended March 31, 2016. In its press release, Alere also stated that it had identified misstatements under U.S. GAAP regarding the timing of revenue recognition in 2013, 2014 and the first three quarters of 2015, and that it expected to file revised 2013 and 2014 financial statements in its 2015 Form 10-K and revised quarterly financial statements for the first three quarters of 2015 in its 2016 quarterly reports when they are filed. Alere has not disclosed an expected filing date for its 2015 Form 10-K. The press release also stated that Alere's management expects to conclude that one or more material weaknesses exist in Alere's internal control over financial reporting in the areas of revenue recognition and income taxes and that, as a result, internal control over financial reporting and disclosure controls and procedures were not effective as of December 31, 2015.

Under the terms of the agreement, Abbott will pay \$56 per common share at a total expected equity value of \$5.8 billion. Alere's net debt, currently \$2.6 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed \$9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing.

On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately \$5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott's global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On July 11, 2016, Abbott and St. Jude Medical received a request for additional information from the United States FTC relating to Abbott's potential acquisition of St. Jude Medical. The effect of this request, which was issued under the HSR Act, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and St. Jude Medical have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive \$46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of \$42.65, which reflects the closing price on July 20, 2016, this represents a value of approximately \$84 per common share at a total expected equity value of approximately \$25 billion. St. Jude Medical's net debt of approximately \$5.7 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed \$17.2 billion in conjunction with its pending acquisition of

St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was \$9.752 billion at June 30, 2016 and \$9.638 billion at December 31, 2015. In the first six months of 2016, foreign currency translation adjustments increased goodwill by approximately \$103 million. There was no purchase price allocation adjustments associated with recent acquisitions made during the six months of 2016. The amount of goodwill related to reportable segments at June 30, 2016 was \$3.0 billion for the Established Pharmaceutical Products segment, \$286 million for the Nutritional Products segment, \$451 million for the Diagnostic Products segment, and \$2.9 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was \$10.9 billion as of June 30, 2016 and \$10.8 billion as of December 31, 2015, and accumulated amortization was \$6.0 billion as of June 30, 2016 and \$5.7 billion as of December 31, 2015. Foreign currency translation adjustments increased intangible assets by \$54 million in the six months of 2016. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately \$390 million and \$419 million as of June 30, 2016 and December 31, 2015, respectively. In the first six months of 2016, Abbott recorded an impairment of a \$43 million in-process research and development project related to a non-reportable segment. Abbott's estimated annual amortization expense for intangible assets is approximately \$580 million in 2016, \$560 million in 2017, \$520 million in 2018, \$490 million in 2019 and \$480 million in 2020. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 14 years).

Note 7 — Restructuring Plans

In 2016, 2015 and 2014, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first six months of 2016, charges of approximately \$13 million were recognized, of which approximately \$7 million is recognized as Cost of products sold and approximately \$6 million as Selling, general and administrative expense. Additional charges of approximately \$2 million were recorded primarily for accelerated depreciation. The following summarizes the activity for the first six months of 2016 related to these restructuring actions and the status of the related accrual as of June 30, 2016:

| (in millions) | |
|--|--------------|
| Accrued balance at December 31, 2015 | \$ 100 |
| Restructuring charges recorded in 2016 | 13 |
| Payments and other adjustments | (25) |
| Accrued balance at June 30, 2016 | <u>\$ 88</u> |

From 2013 to 2015, Abbott management approved various plans to reduce costs and improve efficiencies across various functional areas. In the first six months of 2016, charges of approximately \$12 million were recognized as Selling, general and administrative expense. In 2013, Abbott management also approved plans to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott's established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceuticals and nutritional businesses. The following summarizes the activity for the first six months of 2016 related to these restructuring actions and the status of the related accrual as of June 30, 2016:

| (in millions) | |
|--|--------------|
| Accrued balance at December 31, 2015 | \$ 88 |
| Restructuring charges recorded in 2016 | 12 |
| Payments and other adjustments | (46) |
| Accrued balance at June 30, 2016 | <u>\$ 54</u> |

In 2013 and prior years, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs and improve efficiencies in its worldwide pharmaceutical, vascular and core diagnostics businesses as well as selected domestic and international commercial and research and development operations. The following summarizes the activity for the first six months of 2016 related to these restructuring actions and the status of the related accrual as of June 30, 2016:

| (in millions) | |
|--------------------------------------|-------------|
| Accrued balance at December 31, 2015 | \$ 11 |
| Payments and other adjustments | (4) |
| Accrued balance at June 30, 2016 | <u>\$ 7</u> |

[Table of Contents](#)

Note 8 — Incentive Stock Programs

In the first six months of 2016, Abbott granted 7,699,301 stock options, 776,510 restricted stock awards and 7,341,273 restricted stock units under its incentive stock programs. At June 30, 2016, approximately 56 million shares were reserved for future grants. Information regarding the number of stock options outstanding and exercisable at June 30, 2016 is as follows:

| | Outstanding | Exercisable |
|---|--------------------|--------------------|
| Number of shares | 38,184,610 | 25,540,864 |
| Weighted average remaining life (years) | 5.5 | 3.7 |
| Weighted average exercise price | \$ 33.66 | \$ 30.05 |
| Aggregate intrinsic value (in millions) | \$ 260 | \$ 252 |

The total unrecognized share-based compensation cost at June 30, 2016 amounted to approximately \$280 million which is expected to be recognized over the next three years.

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling \$1.9 billion at June 30, 2016 and \$2.4 billion at December 31, 2015 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2016 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies including the British pound, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2016 and December 31, 2015, Abbott held the gross notional amount of \$15.1 billion and \$14.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately \$516 million and approximately \$439 million as of June 30, 2016 and December 31, 2015, respectively. Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately \$4.0 billion at June 30, 2016 and December 31, 2015 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

[Table of Contents](#)

The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2016 and December 31, 2015:

| (in millions) | Fair Value - Assets | | | Fair Value - Liabilities | | |
|--|---------------------|---------------|--|--------------------------|---------------|---------------------------|
| | June 30, 2016 | Dec. 31, 2015 | Balance Sheet Caption | June 30, 2016 | Dec. 31, 2015 | Balance Sheet Caption |
| Interest rate swaps designated as fair value hedges | \$ 261 | \$ 116 | Deferred income taxes and other assets | \$ — | \$ — | n/a |
| Foreign currency forward exchange contracts: | | | | | | |
| Hedging instruments | 30 | 64 | Prepaid expenses and other receivables | 85 | 18 | Other accrued liabilities |
| Others not designated as hedges | 110 | 115 | Prepaid expenses and other receivables | 76 | 84 | Other accrued liabilities |
| Debt designated as a hedge of net investment in a foreign subsidiary | — | — | n/a | 516 | 439 | Short-term borrowings |
| | <u>\$ 401</u> | <u>\$ 295</u> | | <u>\$ 677</u> | <u>\$ 541</u> | |

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and six months ended June 30, 2016 and 2015. The amount of hedge ineffectiveness was not significant in 2016 and 2015 for these hedges.

| (in millions) | Gain (loss) Recognized in Other Comprehensive Income (loss) | | | | Income (expense) and Gain (loss) Reclassified into Income | | | | Income Statement Caption |
|--|---|------|--------------------------|-------|---|-------|--------------------------|-------|--------------------------|
| | Three Months Ended June 30 | | Six Months Ended June 30 | | Three Months Ended June 30 | | Six Months Ended June 30 | | |
| | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | |
| Foreign currency forward exchange contracts designated as cash flow hedges | \$ 7 | \$ 5 | \$ (51) | \$ 48 | \$ 23 | \$ 30 | \$ 54 | \$ 47 | Cost of products sold |
| Debt designated as a hedge of net investment in a foreign subsidiary | (45) | 11 | (77) | 14 | n/a | n/a | n/a | n/a | n/a |
| Interest rate swaps designated as fair value hedges | n/a | n/a | n/a | n/a | 44 | (63) | 145 | (14) | Interest expense |

Gains of \$20 million and \$85 million were recognized in the three months ended June 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of \$18 million and \$101 million were recognized in the six months ended June 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange loss (gain) line.

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

The carrying values and fair values of certain financial instruments as of June 30, 2016 and December 31, 2015 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to

[Table of Contents](#)

financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

| (in millions) | June 30, 2016 | | December 31, 2015 | |
|------------------------|----------------|------------|-------------------|------------|
| | Carrying Value | Fair Value | Carrying Value | Fair Value |
| Investment Securities: | | | | |
| Equity securities | \$ 3,288 | \$ 3,288 | \$ 4,014 | \$ 4,014 |
| Other | 51 | 54 | 27 | 30 |
| Total Long-term Debt | (6,020) | (6,712) | (5,874) | (6,337) |

| | | | | |
|--|-------|-------|-------|-------|
| Foreign Currency Forward Exchange Contracts: | | | | |
| Receivable position | 140 | 140 | 179 | 179 |
| (Payable) position | (161) | (161) | (102) | (102) |
| Interest Rate Hedge Contracts: | | | | |
| Receivable position | 261 | 261 | 116 | 116 |

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

| | | Basis of Fair Value Measurement | | |
|---|----------------------|---------------------------------|-------------------------------------|---------------------------------|
| (in millions) | Outstanding Balances | Quoted Prices in Active Markets | Significant Other Observable Inputs | Significant Unobservable Inputs |
| June 30, 2016: | | | | |
| Equity securities | \$ 3,030 | \$ 3,030 | \$ — | \$ — |
| Interest rate swap derivative financial instruments | 261 | — | 261 | — |
| Foreign currency forward exchange contracts | 140 | — | 140 | — |
| Total Assets | <u>\$ 3,431</u> | <u>\$ 3,030</u> | <u>\$ 401</u> | <u>\$ —</u> |
| | | | | |
| Fair value of hedged long-term debt | \$ 4,280 | \$ — | \$ 4,280 | \$ — |
| Foreign currency forward exchange contracts | 161 | — | 161 | — |
| Contingent consideration related to business combinations | 162 | — | — | 162 |
| Total Liabilities | <u>\$ 4,603</u> | <u>\$ —</u> | <u>\$ 4,441</u> | <u>\$ 162</u> |
| | | | | |
| December 31, 2015: | | | | |
| Equity securities | \$ 3,780 | \$ 3,780 | \$ — | \$ — |
| Interest rate swap derivative financial instruments | 116 | — | 116 | — |
| Foreign currency forward exchange contracts | 179 | — | 179 | — |
| Total Assets | <u>\$ 4,075</u> | <u>\$ 3,780</u> | <u>\$ 295</u> | <u>\$ —</u> |
| | | | | |
| Fair value of hedged long-term debt | \$ 4,135 | \$ — | \$ 4,135 | \$ — |
| Foreign currency forward exchange contracts | 102 | — | 102 | — |
| Contingent consideration related to business combinations | 173 | — | — | 173 |
| Total Liabilities | <u>\$ 4,410</u> | <u>\$ —</u> | <u>\$ 4,237</u> | <u>\$ 173</u> |

Equity securities are principally comprised of Mylan N.V. ordinary shares. The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines.

[Table of Contents](#)

The following table summarizes the available-for-sale equity securities in an unrealized loss position:

| (in millions) | June 30, 2016 | December 31, 2015 |
|---|---------------|-------------------|
| Fair value of securities in an unrealized loss position | \$ 3,016 | \$ — |
| Unrealized gross losses | 589 | — |

Available-for-sale securities are periodically assessed for other-than-temporary impairment losses. The unrealized losses relate to the holding of Mylan N.V. ordinary shares, which have been in an unrealized loss position for less than six months at June 30, 2016. Factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, Abbott's intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, overall market conditions, and industry and company specific factors. Based on that evaluation and Abbott's ability and intent to hold these investments for a reasonable period of time sufficient for a forecasted recovery of fair value, Abbott does not consider these securities to be other-than-temporarily impaired at June 30, 2016.

Note 10 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed \$4 million, and the aggregate cleanup exposure is not expected to exceed \$10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately \$35 million to \$45 million. The recorded accrual balance at June 30, 2016 for these proceedings and exposures was approximately \$40 million. This accrual represents management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies." Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

Note 11 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net cost recognized in continuing operations for the three months and six months ended June 30 for Abbott's major defined benefit plans and post-employment medical and dental benefit plans is as follows:

| (in millions) | Defined Benefit Plans | | | | Medical and Dental Plans | | | |
|--|----------------------------|-------|--------------------------|--------|----------------------------|--------|--------------------------|-------|
| | Three Months Ended June 30 | | Six Months Ended June 30 | | Three Months Ended June 30 | | Six Months Ended June 30 | |
| | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 |
| Service cost - benefits earned during the period | \$ 67 | \$ 68 | \$ 134 | \$ 150 | \$ 6 | \$ 6 | \$ 13 | \$ 15 |
| Interest cost on projected benefit obligations | 73 | 77 | 146 | 156 | 10 | 11 | 22 | 25 |
| Expected return on plan assets | (143) | (128) | (284) | (257) | (8) | (10) | (17) | (19) |
| Net amortization of: | | | | | | | | |
| Actuarial loss, net | 31 | 42 | 63 | 89 | 3 | 1 | 9 | 10 |
| Prior service cost (credit) | — | — | — | — | (11) | (12) | (22) | (24) |
| Total Cost | 28 | 59 | 59 | 138 | — | (4) | 5 | 7 |
| Less: Discontinued operations | — | — | — | 1 | — | — | — | — |
| Net cost - continuing operations | \$ 28 | \$ 59 | \$ 59 | \$ 137 | \$ — | \$ (4) | \$ 5 | \$ 7 |

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2016 and 2015, \$524 million and \$547 million, respectively, were

[Table of Contents](#)

contributed to defined benefit plans and \$9 million and \$24 million, respectively, were contributed to the post-employment medical and dental benefit plans.

Note 12 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately \$145 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela. Earnings from discontinued operations, net of tax, in the first six months of 2016 reflects the recognition of \$266 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately \$444 million. In the first six months of 2015, taxes on earnings from continuing operations include a tax cost of \$69 million related to the disposal of shares of Mylan stock. Taxes on earnings from continuing operations in the first six months of 2015 were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. 2015 tax expense related to discontinued operations includes \$665 million of tax expense on certain funds earned outside the U.S. in 2015 that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first six months of 2015 also reflects the recognition of \$17 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie's operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately \$35 million.

Tax authorities in various jurisdictions regularly review Abbott's income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by \$100 million to \$200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott's federal income tax returns through 2012 are settled except for one issue.

Note 13 — Segment Information

Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott's products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies throughout the world. Abbott's reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment's assets.

[Table of Contents](#)

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

| (in millions) | Net Sales to External Customers | | | | Operating Earnings | | | |
|--|---------------------------------|-----------------|--------------------------|------------------|----------------------------|---------------|--------------------------|-----------------|
| | Three Months Ended June 30 | | Six Months Ended June 30 | | Three Months Ended June 30 | | Six Months Ended June 30 | |
| | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 |
| Established Pharmaceutical Products | \$ 980 | \$ 977 | \$ 1,868 | \$ 1,874 | \$ 192 | \$ 172 | \$ 340 | \$ 339 |
| Nutritional Products | 1,740 | 1,717 | 3,411 | 3,386 | 368 | 389 | 710 | 739 |
| Diagnostic Products | 1,226 | 1,177 | 2,344 | 2,270 | 288 | 304 | 555 | 580 |
| Vascular Products | 782 | 722 | 1,467 | 1,420 | 290 | 280 | 537 | 564 |
| Total Reportable Segments | 4,728 | 4,593 | 9,090 | 8,950 | 1,138 | 1,145 | 2,142 | 2,222 |
| Other | 605 | 577 | 1,128 | 1,117 | | | | |
| Net Sales | <u>\$ 5,333</u> | <u>\$ 5,170</u> | <u>\$ 10,218</u> | <u>\$ 10,067</u> | | | | |
| Corporate functions and benefit plans costs | | | | | (94) | (104) | (175) | (221) |
| Non-reportable segments | | | | | 52 | 62 | 50 | 117 |
| Net interest expense | | | | | (83) | (17) | (108) | (33) |
| Share-based compensation (a) | | | | | (62) | (57) | (214) | (205) |
| Amortization of intangible assets | | | | | (145) | (151) | (289) | (307) |
| Other, net (b) | | | | | (91) | 108 | (689) | 66 |
| Earnings from continuing operations before taxes | | | | | <u>\$ 715</u> | <u>\$ 986</u> | <u>\$ 717</u> | <u>\$ 1,639</u> |

- (a) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
- (b) Other, net for the six months ended June 30, 2016, includes \$477 million of foreign currency loss related to operations in Venezuela. Other, net for the three months and six months ended June 30, 2015, includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott's revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott's products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott's primary products are nutritional products, branded generic pharmaceuticals, diagnostic testing products and vascular products.

The following table details sales by reportable segment for the three months and six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

| (in millions) | Net Sales to External Customers | | | | |
|-------------------------------------|----------------------------------|----------------------------------|--------------|----------------------------|-------------------------------------|
| | Three Months Ended June 30, 2016 | Three Months Ended June 30, 2015 | Total Change | Impact of Foreign Exchange | Total Change Excl. Foreign Exchange |
| | | | | | |
| Established Pharmaceutical Products | \$ 980 | \$ 977 | 0.4% | (9.1)% | 9.5% |
| Nutritional Products | 1,740 | 1,717 | 1.4 | (2.9) | 4.3 |
| Diagnostic Products | 1,226 | 1,177 | 4.1 | (1.9) | 6.0 |
| Vascular Products | 782 | 722 | 8.3 | (0.6) | 8.9 |
| Total Reportable Segments | 4,728 | 4,593 | 2.9 | (3.6) | 6.5 |
| Other | 605 | 577 | 4.9 | (0.2) | 5.1 |
| Net Sales | <u>\$ 5,333</u> | <u>\$ 5,170</u> | <u>3.2</u> | <u>(3.2)</u> | <u>6.4</u> |
| Total U.S. | <u>\$ 1,655</u> | <u>\$ 1,592</u> | <u>4.0</u> | <u>—</u> | <u>4.0</u> |
| Total International | <u>\$ 3,678</u> | <u>\$ 3,578</u> | <u>2.8</u> | <u>(4.7)</u> | <u>7.5</u> |

| (in millions) | Net Sales to External Customers | | | | |
|-------------------------------------|---------------------------------|--------------------------------|--------------|----------------------------|-------------------------------------|
| | Six Months Ended June 30, 2016 | Six Months Ended June 30, 2015 | Total Change | Impact of Foreign Exchange | Total Change Excl. Foreign Exchange |
| | | | | | |
| Established Pharmaceutical Products | \$ 1,868 | \$ 1,874 | (0.3)% | (10.5)% | 10.2% |

| | | | | | |
|---------------------------|-----------|-----------|-----|-------|-----|
| Nutritional Products | 3,411 | 3,386 | 0.8 | (3.5) | 4.3 |
| Diagnostic Products | 2,344 | 2,270 | 3.2 | (3.2) | 6.4 |
| Vascular Products | 1,467 | 1,420 | 3.3 | (1.7) | 5.0 |
| Total Reportable Segments | 9,090 | 8,950 | 1.6 | (4.6) | 6.2 |
| Other | 1,128 | 1,117 | 1.0 | (1.6) | 2.6 |
| Net Sales | \$ 10,218 | \$ 10,067 | 1.5 | (4.3) | 5.8 |
| | | | | | |
| Total U.S. | \$ 3,186 | \$ 3,094 | 3.0 | — | 3.0 |
| | | | | | |
| Total International | \$ 7,032 | \$ 6,973 | 0.8 | (6.2) | 7.0 |

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Net sales growth in the second quarter and first six months of 2016 was negatively impacted by changes in foreign currency exchange rates. The relatively stronger U.S. dollar decreased total international sales by 4.7 percent and total sales by 3.2 percent in the second quarter. Excluding the unfavorable impact of foreign exchange, total net sales increased 6.4 percent in the second quarter of 2016, driven by higher revenues across all four reportable segments. High single digit growth in emerging market sales contributed to the 7.5 percent increase in total international sales excluding the impact of foreign exchange for the second quarter of 2016.

[Table of Contents](#)

The table below provides detail by sales category for the six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

| (in millions) | June 30, 2016 | June 30, 2015 | Total Change | Impact of Foreign Exchange | Total Change Excl. Foreign Exchange |
|---------------------------------------|------------------|------------------|-----------------|----------------------------------|---|
| Established Pharmaceutical Products — | | | | | |
| Key Emerging Markets | \$ 1,388 | \$ 1,380 | 0.5% | (13.5)% | 14.0% |
| Other Emerging Markets | 480 | 494 | (2.6) | (2.2) | (0.4) |
| Nutritionals — | | | | | |
| International Pediatric Nutritionals | 1,111 | 1,144 | (2.8) | (5.7) | 2.9 |
| U.S. Pediatric Nutritionals | 828 | 786 | 5.3 | — | 5.3 |
| International Adult Nutritionals | 831 | 828 | 0.3 | (6.7) | 7.0 |
| U.S. Adult Nutritionals | 641 | 628 | 2.2 | — | 2.2 |
| Diagnostics — | | | | | |
| Immunochemistry | 1,784 | 1,723 | 3.5 | (3.6) | 7.1 |
| Vascular Products (1) — | | | | | |
| Coronary Devices | 1,099 | 1,099 | 0.1 | (1.7) | 1.8 |
| Endovascular | 278 | 257 | 7.9 | (1.8) | 9.7 |

(1) Coronary Devices include DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products. Endovascular includes vessel closure, carotid stents and other peripheral products.

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 14.0 percent compared to the first six months of 2015 due to continued growth in India, Russia, China and several countries in Latin America. India comprises more than 20 percent of Established Pharmaceutical Product sales.

Excluding the effect of foreign exchange, the 2.9 percent increase in International Pediatric Nutritional sales was primarily driven by strong performance across several countries in Latin America and Asia. In the U.S., the 5.3 percent increase in Pediatric Nutritional sales reflects recent infant and toddler product launches including Similac® Advance® Non-GMO and Go & Grow® by Similac® Non-GMO. Excluding the effect of foreign exchange, the 7.0 percent increase in International Adult Nutritional sales reflects continued strong growth in Latin America and other emerging markets. The 2.2 percent increase in U.S. Adult Nutritional sales was driven by the growth of Ensure® in the retail and institutional market segments.

Excluding the effect of foreign exchange, the 6.4 percent increase in total Diagnostics sales was primarily driven by share gains in the Core Laboratory and Point of Care markets in the U.S. and internationally, including double-digit growth for Core Laboratory in emerging markets. In the Vascular Products segment, double digit growth in sales of Abbott's *MitraClip* structural heart device for the treatment of mitral regurgitation was partially offset by lower sales of DES products. The increase in the Endovascular business was driven by higher *Supera* and vessel closure sales. Vascular Products sales were also favorably impacted by the resolution of previously disputed third party royalty revenue related to the prior year. Excluding this royalty impact, worldwide sales of Vascular Products would have increased 1.2 percent during the first six months of 2016.

The gross profit margin percentage was 54.4 percent for the second quarter of 2016 compared to 54.2 percent for the second quarter of 2015. The gross profit margin percentage was 53.8 percent for the first six months of 2016 compared to 54.2 percent for the first six months of 2015. The decrease for the first six months of 2016 primarily reflects the impact of unfavorable foreign exchange in the nutritional, diagnostic, and vascular businesses.

Research and development expenses increased by \$3 million, or 0.9 percent, in the second quarter of 2016 due primarily to higher spending across various businesses partially offset by a milestone payment recorded in the prior year, while research and development expenses increased by \$69 million, or 10.5 percent, in the first six months

of 2016 due primarily to the impairment of an in-process research and development asset related to a non-reportable segment. For the six months ended June 30, 2016, research and development expenditures totaled \$124 million for the Vascular Products segment, \$255 million for the Diagnostic Products segment, \$65 million for the Established Pharmaceutical Products segment and \$108 million for the Nutritional Products segment.

[Table of Contents](#)

Selling, general and administrative expenses for the second quarter and first six months of 2016 increased 0.6 percent and decreased 0.8 percent, respectively, as higher spending to support the growth of various products was offset by the impact of cost improvement initiatives and the favorable impact of foreign exchange.

Business Acquisitions

In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately \$225 million in cash plus additional payments up to \$150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The preliminary allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately \$220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately \$142 million, other assets of approximately \$13 million, net deferred tax liabilities of approximately \$80 million, and contingent consideration of approximately \$70 million. The preliminary allocations of the fair value of this acquisition will be finalized when the valuation is completed.

Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts.

On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately \$2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott's global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On March 15, 2016, Alere filed a Form 8-K stating that it will not be able to file its 2015 Form 10-K until it completes its analysis of the timing of revenue recognition in Africa and China. In its Form 8-K, Alere also stated that it does not expect to mail a definitive proxy statement related to obtaining the Alere shareholders' approval of the acquisition by Abbott until after Alere files its 2015 Form 10-K. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott's potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

On July 14, 2016, Alere filed a Form 8-K reporting that it had issued a press release announcing certain preliminary unaudited financial information for the fiscal year ended December 31, 2015 and the three months ended March 31, 2016. In its press release, Alere also stated that it had identified misstatements under U.S. GAAP regarding the timing of revenue recognition in 2013, 2014 and the first three quarters of 2015, and that it expected to file revised 2013 and 2014 financial statements in its 2015 Form 10-K and revised quarterly financial statements for the first three quarters of 2015 in its 2016 quarterly reports when they are filed. Alere has not disclosed an expected filing date for its 2015 Form 10-K. The press release also stated that Alere's management expects to conclude that one or more material weaknesses exist in Alere's internal control over financial reporting in the areas of revenue recognition and income taxes and that, as a result, internal control over financial reporting and disclosure controls and procedures were not effective as of December 31, 2015.

Under the terms of the agreement, Abbott will pay \$56 per common share at a total expected equity value of \$5.8 billion. Alere's net debt, currently \$2.6 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed \$9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing.

On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately \$5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott's global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On July 11, 2016, Abbott and St. Jude Medical received a request for additional information from the United States FTC relating to Abbott's potential acquisition of St. Jude Medical. The effect of this request, which was issued under the HSR Act, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and St. Jude Medical have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive \$46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of \$42.65, which reflects the closing price on July 20, 2016, this represents a

[Table of Contents](#)

value of approximately \$84 per common share at a total expected equity value of approximately \$25 billion. St. Jude Medical's net debt of approximately \$5.7 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed \$17.2 billion in conjunction with its pending acquisition of St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

Restructuring Plans

The results for the first six months of 2016 reflect charges recognized for actions associated with the company's plans to streamline various operations in order to reduce costs and improve efficiencies. Abbott recorded employee related severance and other charges of approximately \$25 million in 2016 related to these initiatives. Approximately \$7 million is recognized in Cost of products sold and approximately \$18 million is recognized in Selling, general and administrative expense. See Note 7 to the financial statements, "Restructuring Plans," for additional information regarding these charges.

Interest Expense (Income), net

Interest expense (income), net increased \$66 million in the second quarter of 2016 and \$75 million in the first six months of 2016 compared to 2015 due to higher interest expense in 2016 associated with the amortization of bridge financing fees related to the financing of the two pending acquisitions. The increase in the first six months of 2016 also reflects higher interest expense related to the long-term debt issued in March of 2015.

Taxes on Earnings from Continuing Operations

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately \$145 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela. Earnings from discontinued operations, net of tax, in the first six months of 2016 reflects the recognition of \$266 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately \$444 million. In the first six months of 2015, taxes on earnings from continuing operations include a tax cost of \$69 million related to the disposal of shares of Mylan stock. Taxes on earnings from continuing operations in the first six months of 2015 were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. 2015 tax expense related to discontinued operations includes \$665 million of tax expense on certain funds earned outside the U.S. in 2015 that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first six months of 2015 also reflects the recognition of \$17 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie's operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately \$35 million.

Tax authorities in various jurisdictions regularly review Abbott's income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by \$100 million to \$200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott's federal income tax returns through 2012 are settled except for one issue.

Separation of AbbVie Inc.

On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott's research-based proprietary pharmaceuticals business. For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 and 2014. These assets and liabilities have been presented as held for disposition in the Condensed Consolidated Balance Sheet. Abbott has recorded a prepaid asset of \$293 million for its obligation to transfer these net liabilities held for disposition to AbbVie.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Net earnings from discontinued operations reflect the recognition of a net tax benefit of \$263 million and \$17 million in the first six months of 2016 and 2015, respectively, as a result of the resolution of various tax positions related to AbbVie's operations for years prior to the separation.

[Table of Contents](#)

Discontinued Operations

As a result of the disposition of Abbott's developed markets branded generics pharmaceuticals and animal health businesses, the current and prior years' operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from discontinued operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses are included in Abbott's Condensed Consolidated Statement of Cash Flows up to the date of disposition.

The operating results of Abbott's developed markets branded generics pharmaceuticals, animal health and AbbVie businesses, which are being reported as discontinued operations are as follows:

| (in millions) | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|-------------------------------|--------|-----------------------------|--------|
| | 2016 | 2015 | 2016 | 2015 |
| Net Sales | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ — | \$ — | \$ — | \$ 256 |
| AbbVie | — | — | — | — |
| Total | \$ — | \$ — | \$ — | \$ 256 |
| Earnings (Loss) Before Tax | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ (3) | \$ (5) | \$ (6) | \$ 20 |
| AbbVie | — | — | — | — |
| Total | \$ (3) | \$ (5) | \$ (6) | \$ 20 |
| Income Tax Expense (Benefit) | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ — | \$ — | \$ (3) | \$ 12 |
| AbbVie | (19) | (4) | (263) | (17) |
| Total | \$ (19) | \$ (4) | \$ (266) | \$ (5) |
| Net Earnings (Loss) | | | | |
| Developed markets generics pharmaceuticals and animal health businesses | \$ (3) | \$ (5) | \$ (3) | \$ 8 |
| AbbVie | 19 | 4 | 263 | 17 |

| | | | | |
|-------|-------|--------|--------|-------|
| Total | \$ 16 | \$ (1) | \$ 260 | \$ 25 |
|-------|-------|--------|--------|-------|

In the first six months of 2016, Abbott received an additional \$25 million of proceeds related to the expiration of a holdback agreement associated with the sale of the animal health business and reported an after-tax gain on the sale in discontinued operations of \$16 million. The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first six months of 2015 resulted in the recognition of a pretax gain of \$2.820 billion, tax expense of \$1.084 billion and an after tax gain of \$1.736 billion.

The assets and liabilities held for disposition as of June 30, 2016 and December 31, 2015, relate to the AbbVie businesses. The following is a summary of the assets and liabilities held for disposition:

| (in millions) | June 30, 2016 | December 31, 2015 |
|--|------------------|----------------------|
| Cash and Trade receivables, net | \$ 41 | \$ 54 |
| Total inventories | 20 | 43 |
| Prepaid expenses and other receivables | 5 | 8 |
| Current assets held for disposition | 66 | 105 |
| Net property and equipment | 1 | 1 |
| Deferred income taxes and other assets | 1 | 1 |
| Non-current assets held for disposition | 2 | 2 |
| Total assets held for disposition | \$ 68 | \$ 107 |
| Trade accounts payable | \$ 360 | \$ 359 |
| Salaries, wages, commissions and other accrued liabilities | 1 | 14 |
| Current liabilities held for disposition | 361 | 373 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | — | — |
| Total liabilities held for disposition | \$ 361 | \$ 373 |

[Table of Contents](#)

Liquidity and Capital Resources June 30, 2016 Compared with December 31, 2015

The reduction of cash and cash equivalents from \$5.0 billion at December 31, 2015 to \$2.6 billion at June 30, 2016 reflects repayment of short-term debt, pension contributions, share repurchases and the Venezuela foreign currency loss, as well as dividends paid during the year and an increase in short-term investments.

Net cash from operating activities for the first six months of 2016 totaled \$816 million. Other, net in Net cash from operating activities for the first six months of 2016 of \$1.2 billion includes contributions to defined benefit pension plans of \$524 million as well as approximately \$140 million of cash taxes paid related to the disposition of businesses. Other, net in 2016 also includes the non-cash impact of approximately \$410 million of net tax benefits primarily associated with the resolution of various tax positions from prior years. In the first six months of 2015, Other, net in Net cash from operating activities included the contributions to defined benefit pension plans of \$547 million, as well as approximately \$95 million related to cost reduction and business disposal activities. Other, net in 2015 also included the non-cash impact of \$1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first six months of 2016 reduced Abbott's cash by approximately \$410 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows. Abbott expects to fund cash dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.

Working capital was \$4.3 billion at June 30, 2016 and \$5.0 billion at December 31, 2015. The \$0.7 billion decrease in working capital in 2016 is primarily due to the reduction in Cash and cash equivalents driven by pension contributions, share repurchases, the Venezuela foreign currency loss and dividends paid.

A majority of Abbott's trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. Governmental receivables in these four countries accounted for less than 1% of Abbott's total assets and 8% of total net trade receivables as of June 30, 2016 as compared to less than 1% of total assets and 7% of total net trade receivables as of December 31, 2015. With the exception of Greece, Abbott historically has collected almost all of the outstanding receivables in these countries. Abbott closely monitors economic conditions and budgetary and other fiscal developments in these countries. Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate risk although such arrangements were not material in the first six months of 2016.

Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. GAAP. In 2014 and 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. These mechanisms included the CENCOEX, SICAD, and SIMADI rates, which stood at 6.3, 13.5, and approximately 200, respectively, at December 31, 2015. In 2015, Abbott continued to use the CENCOEX rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela.

On February 17, 2016, the Venezuelan government announced that the three-tier exchange rate system would be reduced to two rates renamed the DIPRO and DICOM rates. The DIPRO rate is the official rate for food and medicine imports and was adjusted from 6.3 to 10 bolivars per U.S. dollar. The DICOM rate is a floating market rate published daily by the Venezuelan central bank, which at the end of the first quarter of 2016 was approximately 263 bolivars per U.S. dollar. As a result of decreasing government approvals to convert bolivars to U.S. dollars to pay for intercompany accounts, as well as the accelerating deterioration of economic conditions in the country, Abbott concluded that it was appropriate to move to the DICOM rate at the end of the first quarter of 2016. As a result, Abbott recorded a foreign currency loss of \$477 million in the first quarter of 2016 to revalue its net monetary assets in Venezuela. Abbott is continuing to use the DICOM rate to report the results of operations and to remeasure net monetary assets for Venezuela at the end of each quarter. As of June 30, 2016, Abbott's Venezuelan operations represented approximately 0.1% of Abbott's consolidated assets and any additional foreign currency losses related to Venezuela are not expected to be material.

At June 30, 2016, Abbott's long-term debt rating was A+ by Standard & Poor's Corporation and A2 by Moody's Investors Service. As a result of Abbott's announced agreements to acquire Alere and St. Jude Medical, Abbott's credit ratings are under review and it is anticipated that the ratings will be adjusted to reflect the increased borrowings that will be incurred to finance these acquisitions. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources,

including unused lines of credit of \$5.0 billion that support commercial paper borrowing arrangements which expire in 2019.

In September 2014, the board of directors authorized the repurchase of up to \$3.0 billion of Abbott's common shares from time to time. The 2014 authorization was in addition to the \$512 million unused portion of a previous program announced in June 2013. In the first six months of 2016, Abbott repurchased 10.4 million shares at a cost of \$408 million under the program authorized in 2014. In the first six months of 2015, Abbott repurchased 11.3 million shares at a cost of \$512 million under the unused portion of the 2013

[Table of Contents](#)

authorization and 15.6 million shares at a cost of \$738 million under the program authorized in 2014 for a total of 26.9 million shares at a cost of \$1.25 billion.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to \$3 billion.

In each of the first two quarters of 2016, Abbott declared a quarterly dividend of \$0.26 per share on its common shares, which represents an 8% increase over the \$0.24 per share quarterly dividend declared in each of the first two quarters of 2015.

[Recently Issued Accounting Standards](#)

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, *Improvements to Employee Share-Based Payment Accounting*. ASU 2016-09 modifies several aspects of the accounting for share-based payment transactions, including the accounting for income taxes and classification on the statement of cash flows. The standard becomes effective for Abbott beginning in the first quarter of 2017 and early adoption is permitted. Abbott does not anticipate that the new guidance will have a material impact on its consolidated financial statements. Abbott cannot predict the impact on its consolidated financial statements in future reporting periods following adoption as this will be dependent upon various factors including the number of shares issued and changes in the price of its shares.

In February 2016, the FASB issued ASU 2016-02, *Leases*, which requires lessees to recognize assets and liabilities for most leases on the balance sheet. The standard becomes effective for Abbott beginning in the first quarter of 2019 and early adoption is permitted. Adoption requires application of the new guidance for all periods presented. Abbott is currently evaluating the impact the new guidance will have on its consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, *Financial Instruments — Recognition and Measurement of Financial Assets and Financial Liabilities*, which provides new guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The standard becomes effective for Abbott beginning in the first quarter of 2018 and early adoption is permitted. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers*, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

[Legislative Issues](#)

Abbott's primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K and in Item 1A, Risk Factors, in the quarterly report for the quarter ended June 30, 2016.

[Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements](#)

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K and in Item 1A, Risk Factors, in the quarterly report for the quarter ended June 30, 2016.

[Table of Contents](#)

PART I. FINANCIAL INFORMATION

[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#)

Market Price Sensitive Investments

The fair value of the available-for-sale equity securities held by Abbott was approximately \$3.0 billion as of June 30, 2016 and \$3.8 billion as of December 31, 2015. The decrease is due primarily to a decrease in the share price of the ordinary shares of Mylan N.V. that Abbott received in the sale of its developed markets branded generics pharmaceuticals business and that it continued to hold at June 30, 2016. All available-for-sale equity securities are subject to potential changes in market value. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at June 30, 2016 by approximately \$600 million. Abbott monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in value occurs.

[Item 4. Controls and Procedures](#)

- (a) *Evaluation of disclosure controls and procedures.* The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories' disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories' disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
- (b) *Changes in internal control over financial reporting.* During the quarter ended June 30, 2016, there were no changes in Abbott's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including (as of June 30, 2016, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

In May 2016, two purported shareholder derivative class action lawsuits were filed against St. Jude Medical, its board of directors, and Abbott and two of its subsidiaries in the Minnesota District Court, Second Judicial District (Ramsey County). Plaintiffs allege, among other things, that the members of the St. Jude Medical board of directors breached its fiduciary duties to St. Jude Medical shareholders by entering into the agreement, and that Abbott aided and abetted those breaches. Plaintiffs seek injunctive relief, as well as actual and punitive damages. Abbott denies all substantive allegations in the case.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in Abbott's 2015 Form 10-K, except for the following:

Fluctuation in foreign currency exchange rates may adversely affect our financial statements and Abbott's ability to realize projected sales and earnings.

Although Abbott's financial statements are denominated in U.S. dollars, a significant portion of Abbott's revenues and costs are realized in other currencies. Sales outside of the United States make up approximately 70 percent of Abbott's net sales. Abbott's profitability is affected by movement of the U.S. dollar against other currencies. Fluctuations in exchange rates between the U.S. dollar and other currencies may also affect the reported value of Abbott's assets and liabilities, as well as its cash flows. Some foreign

[Table of Contents](#)

currencies are subject to government exchange controls. While Abbott enters into hedging arrangements to mitigate some of its foreign currency exposure, Abbott cannot predict with any certainty changes in foreign currency exchange rates or its ability to mitigate these risks.

Information on the impact of foreign exchange rates on Abbott's financial results is contained in the "Financial Review — Results of Operations" section in Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations of this report. A discussion of the steps taken to mitigate the impact of foreign exchange is contained in Item 7A, Quantitative and Qualitative Disclosures about Market Risk in Abbott's 2015 Form 10-K. Information on Abbott's hedging arrangements is contained in Note 9 to the consolidated financial statements in this report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) *Issuer Purchases of Equity Securities*

| Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|--------------------------------|---|--|---|---|
| April 1, 2016 – April 30, 2016 | 4,421 ⁽¹⁾ | \$ 43.470 | — | \$ 925,131,209 ⁽²⁾ |
| May 1, 2016 – May 31, 2016 | 37,633 ⁽¹⁾ | \$ 37.826 | — | \$ 925,131,209 ⁽²⁾ |
| June 1, 2016 – June 30, 2016 | 23,127 ⁽¹⁾ | \$ 37.707 | — | \$ 925,131,209 ⁽²⁾ |
| Total | 65,181 ⁽¹⁾ | \$ 38.166 | — | \$ 925,131,209 ⁽²⁾ |

(1) These shares include:

- (i) the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options — 4,421 in April, 1,633 in May, and 5,127 in June; and
- (ii) the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan — 0 in April, 36,000 in May, and 18,000 in June.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

- (2) On September 11, 2014, Abbott announced that its board of directors approved the purchase of up to \$3 billion of its common shares, from time to time.

Item 6. Exhibits

Incorporated by reference to the Exhibit Index included herewith.

27

[Table of Contents](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES

By: /s/ Brian B. Yoor
Brian B. Yoor
Senior Vice President, Finance
and Chief Financial Officer

Date: August 3, 2016

28

[Table of Contents](#)

EXHIBIT INDEX

| <u>Exhibit No.</u> | <u>Exhibit</u> |
|---|--|
| 12 | Statement re: Computation of ratio of earnings to fixed charges. |
| 31.1 | Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)). |
| 31.2 | Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)). |
| Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be "filed" under the Securities Exchange Act of 1934. | |
| 32.1 | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2 | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 | The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and six months ended June 30, 2016, formatted in XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements. |

29
